drugset
drugset / Trial / NCT01509053

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

NCT01509053 ↗

Phase 3 Terminated 30 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.

Timeline

Start
2012-01
Primary completion
2012-10
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 10 mg Intramuscular
Subject Aripiprazole Other / unclassified 15 mg Intramuscular
Subject Aripiprazole Other / unclassified 30 mg Intramuscular
Subject Aripiprazole Other / unclassified 300 mg Intramuscular
Subject Aripiprazole Other / unclassified 400 mg Intramuscular

Indications

schizophrenia